Related Experiment Videos
Fibrinolysis and fibrinogenolysis in patients with thrombotic disease
H Takahashi1, K Wada, M Hanano
1First Department of Internal Medicine, Niigata University School of Medicine, Japan.
Insights
Patients with thrombotic diseases show elevated fibrin degradation products (FbDP) and fibrinogen degradation products (FgDP). These markers, particularly prominent in venous thrombosis, indicate accelerated fibrinolysis and concurrent fibrinogenolysis.
Area of Science:
- Hematology
- Thrombosis Research
- Fibrinolysis
Background:
- Thrombotic diseases are associated with complex hemostatic alterations.
- Understanding the fibrinolytic state is crucial for managing thrombotic conditions.
Purpose of the Study:
- To assess the fibrinolytic state in patients with various thrombotic diseases.
- To quantify plasma levels of fibrin degradation products (FbDP) and fibrinogen degradation products (FgDP).
Main Methods:
- Plasma levels of FbDP and FgDP were measured.
- 126 patients with diverse thrombotic diseases were included.
- Comparison was made with healthy subjects.
Main Results:
- Mean plasma concentrations of FbDP and FgDP were significantly elevated in thrombotic disease patients versus controls.
- FgDP levels positively correlated with FbDP (r = 0.667, P < 0.001).
- Elevations were most pronounced in venous thrombotic diseases like deep vein thrombosis and pulmonary embolism.
Conclusions:
- Fibrinolysis is accelerated in patients with thrombotic disease.
- Fibrinolysis is frequently accompanied by fibrinogenolysis in these patients.
- Findings highlight the role of fibrinolysis and fibrinogenolysis in thrombotic pathophysiology.
Abstract:
In order to assess the fibrinolytic state in thrombotic disease, plasma levels of fibrin degradation products (FbDP) and fibrinogen degradation products (FgDP) were measured in 126 patients with a variety of thrombotic diseases. Mean plasma concentrations of both FbDP and FgDP were significantly elevated in patients with thrombotic disease as compared with healthy subjects. Plasma concentrations of FgDP were positively correlated with FbDP (r = 0.667, P less than 0.001). When analysed according to the disease categories, the magnitude of elevations of FbDP and FgDP was most prominent in venous thrombotic disease such as deep vein thrombosis and pulmonary embolism. These findings indicate that fibrinolysis is accelerated in patients with thrombotic disease and that fibrinolysis is frequently accompanied by some fibrinogenolysis in these patients.